Hiv/aids news and hiv/aids widget

Ninety-six week results presented from a phase 3, randomized, open-label, ongoing clinical trial showed that 79 percent of treatment-naive HIV-1 infected adults taking PREZISTA(R) 800 mg (two 400 mg tablets) with 100 mg ritonavir (r) once daily reached an undetectable viral load (

At the 20th. Annual Living with AIDS Conference in Utah, experts warn that the booming crystal meth problem is contributing to new hiv cases around the country. The growing cocaine...

This is going to sound a bit crazy but I was watching television a couple nights ago and stumbled upon a vampire movie. Like all good Hollywood vampires, they were...

A recent study published in The Lancet has found that the proportion of IV drug users that are HIV positive may exceed 40 percent in at least nine countries around...

On Friday, two Minnesota radio talk show hosts claimed that Magic Johnson faked his HIV diagnosis. The talk show hosts have rationalized that Magic must have faked his diagnosis because...

Patients taking Selzentry, in combination with Combivir® (zidovudine/lamivudine) and selected by an enhanced sensitivity tropism test to screen patients, experienced a 68 percent rate of virologic suppression to undetectable levels, according to the MERIT ES (Reanalysis of the MERIT Study wit

Panacos Pharmaceuticals, Inc. (NASDAQ: PANC), a biotechnology company dedicated to developing the next generation of antiviral therapeutic products, today announced that data from the Company's Phase 2b study of bevirimat, Panacos' lead HIV-1 Gag maturation inhibitor, was shown in an oral presentation at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Washington, DC.

What: Under current treatment guidelines, highly active antiretroviral therapy (HAART) should be considered for HIV-infected patients when their CD4+ T-cell counts fall below 350 cells per cubic millimeter (mm3). However, new epidemiological research suggests that patients with HIV may have less risk of dying if they begin HAART sooner. HIV ravages CD4+ T-cells, one of the human immune system's primary weapons for fighting off infection.

HIV and sexual health charity, Terrence Higgins Trust (THT) is relaunching its membership scheme today and is calling on people to join. Membership is free and provides an opportunity to get fully involved in THT's work or just show support by signing up. Members will be kept up to date on the latest HIV and sexual health news and will get three e-newsletters a year, keeping them informed on sexual health issues, THT's work, campaigns and fundraising activities.

Half of the 2008 Nobel Prize in medicine will be shared by two researchers credited with their discovery of HIV. French researchers Luc Montagnier and Francoise Barre-Sinoussi will be honored...